Trial Profile
A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs PBT 2 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms IMAGINE
- Sponsors Alterity Therapeutics
- 17 Jul 2014 According to the Prana Biotechnology media release, data from this trial was presented at the Alzheimer's Association International Conference 12-14 Jul 2014.
- 31 Mar 2014 Status changed from active, no longer recruiting to completed, as reported in a Prana Biotechnology media release.
- 31 Mar 2014 Top-line results reported in a Prana Biotechnology media release.